Charles Schwab Investment Management Inc. Has $1.54 Million Holdings in Capricor Therapeutics Inc (NASDAQ:CAPR)

Charles Schwab Investment Management Inc. raised its stake in Capricor Therapeutics Inc (NASDAQ:CAPR) by 51.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 111,336 shares of the biotechnology company’s stock after buying an additional 37,868 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.24% of Capricor Therapeutics worth $1,536,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Oppenheimer & Co. Inc. increased its stake in shares of Capricor Therapeutics by 52.4% in the 4th quarter. Oppenheimer & Co. Inc. now owns 104,231 shares of the biotechnology company’s stock valued at $1,438,000 after acquiring an additional 35,823 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Capricor Therapeutics by 32.6% during the fourth quarter. Bank of New York Mellon Corp now owns 84,027 shares of the biotechnology company’s stock valued at $1,160,000 after purchasing an additional 20,638 shares during the period. Black Diamond Financial LLC bought a new stake in Capricor Therapeutics in the fourth quarter valued at approximately $3,833,000. New York State Common Retirement Fund raised its holdings in Capricor Therapeutics by 625.0% in the fourth quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 5,000 shares during the period. Finally, Rhumbline Advisers boosted its position in shares of Capricor Therapeutics by 44.4% during the fourth quarter. Rhumbline Advisers now owns 46,083 shares of the biotechnology company’s stock worth $636,000 after purchasing an additional 14,169 shares in the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

Analyst Upgrades and Downgrades

CAPR has been the subject of a number of recent analyst reports. Cantor Fitzgerald restated an “overweight” rating and issued a $30.00 price objective on shares of Capricor Therapeutics in a research report on Thursday, March 20th. HC Wainwright restated a “buy” rating and issued a $77.00 price target on shares of Capricor Therapeutics in a report on Monday, March 17th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company. Based on data from MarketBeat, Capricor Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $34.50.

Capricor Therapeutics Trading Down 2.6 %

CAPR stock opened at $11.50 on Friday. The stock has a 50-day moving average price of $14.00 and a two-hundred day moving average price of $14.92. Capricor Therapeutics Inc has a 1 year low of $3.52 and a 1 year high of $23.40. The stock has a market cap of $522.91 million, a PE ratio of -10.85 and a beta of 4.10.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.15. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. The business had revenue of $11.13 million during the quarter, compared to the consensus estimate of $9.87 million. On average, analysts forecast that Capricor Therapeutics Inc will post -1.21 earnings per share for the current fiscal year.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.